Correlating plasma nintedanib concentrations with clinical outcome and toxicity in patients with interstitial lung disease
Latest Information Update: 27 Aug 2021
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases; Pulmonary fibrosis
- Focus Pharmacokinetics
- Acronyms CONCORDIA
- 27 Aug 2021 New trial record